Haemonetics CEO Chris Simon to Present at J.P. Morgan Healthcare Conference on January 13, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Newsfilter
- Conference Schedule: Haemonetics CEO Chris Simon will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 7:30 AM Pacific Time, showcasing the company's latest advancements in medical technology.
- Live Access: The public can access Simon's presentation live via the Events & Presentations section of Haemonetics' Investor Relations website, enhancing interaction and transparency between the company and its investors.
- Replay Availability: A replay of the presentation will be available approximately one hour after the live event on Haemonetics' Investor Relations website, providing convenience for investors who cannot attend in real-time.
- Company Background: Haemonetics is a global medical technology company focused on improving healthcare quality and efficiency, with innovative solutions that include hospital technologies and plasma collection systems aimed at optimizing operations and enhancing patient outcomes.
Analyst Views on HAE
Wall Street analysts forecast HAE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for HAE is 78.86 USD with a low forecast of 64.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 80.980
Low
64.00
Averages
78.86
High
90.00
Current: 80.980
Low
64.00
Averages
78.86
High
90.00
About HAE
Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
